Abemaciclib

About

Therapy type: Targeted therapy

Therapy strategy: CDK4/6 inhibition

Mappings

NCI Thesaurus: Abemaciclib (coding:ncit:C97660)

RxNorm: abemaciclib (coding:rxcui:1946825, coding:omop:792649)

SNOMED: Abemaciclib (coding:sctid:761851004, coding:omop:42539316)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations Biomarkers Cancer types Therapies
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane